Technical Analysis for GLUE - Monte Rosa Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 5.23 | -0.57% | -0.03 |
Earnings due: May 9
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 200 DMA | Bearish | -0.57% | |
| MACD Bearish Signal Line Cross | Bearish | -0.57% | |
| Wide Bands | Range Expansion | -0.57% | |
| 20 DMA Resistance | Bearish | -7.92% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -7.92% | |
| MACD Bullish Signal Line Cross | Bullish | -7.92% | |
| Wide Bands | Range Expansion | -7.92% | |
| Gapped Up | Strength | -7.92% | |
| Outside Day | Range Expansion | -9.20% | |
| Wide Bands | Range Expansion | -9.20% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | 38 minutes ago |
| 1.5x Volume Pace | about 1 hour ago |
| Possible NR7 | about 2 hours ago |
| Down 3% | about 6 hours ago |
| Fell Below Previous Day's Low | about 6 hours ago |
Get a Trading Assistant
- Earnings date: 05/09/2024
Monte Rosa Therapeutics, Inc. Description
Monte Rosa Therapeutics is a biotechnology company developing a portfolio of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins. The company has developed a proprietary protein degradation platform, called QuEEN™, that enables it to rapidly identify protein targets and molecular glue degrader, or MGD, product candidates that are designed to eliminate therapeutically relevant proteins in a highly selective manner. The company’s drug discovery platform combines diverse and proprietary chemical libraries of small molecule protein degraders with in-house proteomics, structural biology, machine learning-based target selection and computational chemistry capabilities to predict and obtain protein degradation profiles. Monte Rosa was launched from founding investor Versant Ventures’ Ridgeline Discovery Engine and is headquartered in Boston, Mass., with research operations in both Boston and Basel, Switzerland.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Drug Discovery Machine Learning Proteomics
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.84 |
| 52 Week Low | 2.44 |
| Average Volume | 137,100 |
| 200-Day Moving Average | 5.43 |
| 50-Day Moving Average | 6.39 |
| 20-Day Moving Average | 5.83 |
| 10-Day Moving Average | 5.56 |
| Average True Range | 0.50 |
| RSI (14) | 39.39 |
| ADX | 14.24 |
| +DI | 17.79 |
| -DI | 23.04 |
| Chandelier Exit (Long, 3 ATRs) | 6.71 |
| Chandelier Exit (Short, 3 ATRs) | 6.62 |
| Upper Bollinger Bands | 6.91 |
| Lower Bollinger Band | 4.76 |
| Percent B (%b) | 0.23 |
| BandWidth | 36.87 |
| MACD Line | -0.29 |
| MACD Signal Line | -0.28 |
| MACD Histogram | -0.0086 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 6.04 | ||||
| Resistance 3 (R3) | 6.10 | 5.89 | 5.91 | ||
| Resistance 2 (R2) | 5.89 | 5.69 | 5.87 | 5.87 | |
| Resistance 1 (R1) | 5.58 | 5.57 | 5.48 | 5.52 | 5.82 |
| Pivot Point | 5.37 | 5.37 | 5.32 | 5.35 | 5.37 |
| Support 1 (S1) | 5.06 | 5.17 | 4.96 | 5.00 | 4.70 |
| Support 2 (S2) | 4.85 | 5.05 | 4.83 | 4.65 | |
| Support 3 (S3) | 4.54 | 4.85 | 4.61 | ||
| Support 4 (S4) | 4.48 |
